June 15, 2012 — Lone Oak Medical Technologies announced that the U.S. Food and Drug Administration (FDA) has approved its AccuDXA2 bone mineral density assessment system for the U.S. market. Unlike Central DXA devices that measure the bone mineral density (BMD) of the hip and spine, the AccuDXA2 peripheral DXA (pDXA) device accurately measures the bone density of the finger — a site with over 50 years of clinical acceptance.
The AccuDXA2 BMD assessment system features an enhanced form of X-ray technology to measure bone density, called dual-energy X-ray absorptiometry, or DXA. The AccuDXA2 employs a very low radiation dosage (0.0003 uSv), or 1/150,000 of a typical chest X-ray, to produce its screenings.
BMD is an appropriate parameter by which to monitor changes in bone mineral density, effected by drug therapy or aging. Physicians are encouraged to compare results of BMD tests taken on a patient over a period of time with the reported AccuDXA2 precision (repeatability).
"The AccuDXA2 offers an aging population a convenient and affordable alternative to time-consuming hospital visits for Central DXA testing," said Alan Keim, president of Lone Oak Medical Technologies. "Screenings can now take place in neighborhood clinics and doctor offices. Scan times are less than ten seconds, and the complete exam can be completed in two minutes."
Other benefits include cost effectiveness and a data archive for storing patient test records. The system is also clinically proven: a 2009 Rancho Bernardo Study indicated the importance of measuring BMD of the phalanges by comparing BMD obtained with AccuDXA2 with BMD of the total hip obtained by DXA, as well as comparing the association of phalange BMD with osteoporotic fractures.
For more information: www.loneoakmedical.com
March 25, 2026 
